May 28, 2009 / 9:25 PM / in 10 years

Companies starting work on H1N1 vaccine: CDC

CHICAGO (Reuters) - Companies are starting preliminary work on a vaccine for the new H1N1 flu and should begin clinical trials in the coming months, but the new vaccine would not be ready for widespread use until October, U.S. health officials said on Thursday.

A researcher works on a vaccine for H1N1 flu virus at the Infectious Disease Laboratory at the Centers for Disease Control in Atlanta, Georgia May 6, 2009. REUTERS/Tami Chappell

Although new to humans, they said, the H1N1 strain appears to be behaving very much like a seasonal H1N1 flu in striking more children and young people.

So far, there have been 8,585 probable and confirmed U.S. cases of the new H1N1 strain, commonly called swine flu, with 12 deaths and 507 hospitalizations, Dr. Anne Schuchat of the U.S. Centers for Disease Control and Prevention said in a telephone briefing.

She said the CDC shipped virus samples for making vaccines to different manufacturers several days ago.

The strains were made using traditional vaccine methods, which involve live vaccines made in chicken eggs, and a new, proprietary reverse genetics method that allows companies to make non-live vaccines, avoiding working with potentially highly infectious pandemic strains.

AstraZeneca’s MedImmune unit owns the reverse genetics method, which it has licensed to a number of companies approved to sell flu shots in the United States including Sanofi-Aventis SA, Novartis AG and GlaxoSmithKline Plc.

Schuchat said in coming weeks companies will start making “candidate lots” of vaccine which will be used for clinical trials. “Those will happen over the summer months,” she said.

Clinical trials will need to answer a number of questions, Schuchat said, including whether one or two injections will be needed, whether vaccinating different age groups yields different results and whether an immune system booster called an adjuvant would be needed to get a good response.


She said companies are also developing bulk ingredients needed to make vaccine doses should the CDC decide a vaccine is needed.

“The actual making of those doses needs to wait for the clinical studies to be finished,” she said.

She said the decision on whether to produce large quantities of a vaccine would be made later in the Northern Hemisphere summer or early autumn.

The CDC and World Health Organization will be taking their cues from the way this flu behaves in the Southern Hemisphere, where flu season is just starting.

“Most of the people that are getting sick continue to be in that 5-to-24-year age group. That’s 62 percent of all the cases that we’re counting,” Schuchat told the briefing.

She said it is still “relatively rare” for people over 55 to be infected, with only about 1 percent of probable cases in that age range.

While there is no question the flu strain is new, Schuchat said in some respects it is behaving a bit like the seasonal H1N1 flu strain that circulates every year.

“Seasonal H1N1 often causes more disease in younger people,” she said.

She also gave details of how to tell who is at most risk of becoming severely ill with any respiratory disease, so they know when to seek immediate medical help.

Children who look blue or cannot be awakened should be taken to a doctor, she said. “Being so irritable that the child doesn’t want to be held. Flu-like symptoms improve, but then return later with a fever and a worse cough,” she said.

For adults, severe vomiting is a danger sign, as is sudden dizziness and chest pressure.

Editing by Mohammad Zargham

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below